SynthesisViruses2024
(Re-)Emergence of Oropouche Virus (OROV) Infections: Systematic Review and Meta-Analysis of Observational Studies.
Synthesis in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Serological and viral prevalence of Oropouche virus (OROV): A systematic review and meta-analysis from 2000-2024 including human, animal, and vector surveillance studies.PLoS neglected tropical diseases · 2025Pooled it
- Risk of Nipah Virus Seroprevalence in Healthcare Workers: A Systematic Review with Meta-Analysis.Viruses · 2025Pooled it
- Pooled it
- In silico pharmacological evaluation of a multi-epitope vaccine candidate targeting the G1 and G2 glycoproteins of Oropouche virus via TLR3 interaction.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Review
- Phylogeographic dynamics of oropouche virus in the Colombian Amazon: Evolutionary insights in a climatic context.PLoS neglected tropical diseases · 2026Article
- Immunoinformatic based Development of a Multi-Epitope Precision Vaccine Targeting Glycoprotein and RdRp of Oropouche Virus:Saudi medical journal · 2026Article
- Oropouche virus outbreaks in northeast Brazil between 2024-25 are characterized by sustained transmission and spread to newly affected areas.PLoS neglected tropical diseases · 2026Article
- Susceptibility of Livestock, Wildlife, and Domestic Host Species Cells to the 2022-2025 Reassortant Oropouche Virus.Pathogens (Basel, Switzerland) · 2026Article
- Clinical and Epidemiological Characteristics of an Oropouche Virus Outbreak in Loreto, Peru (October 2024-March 2025).Pathogens (Basel, Switzerland) · 2026Observational
- Metatranscriptomic Identification of Trubanaman Virus Sequences in Patient with Encephalitis, Australia.Emerging infectious diseases · 2025Article
- Dengue and Acute Pancreatitis: A Systematic Review.Tropical medicine and infectious disease · 2025Review
- Structure-Based Identification of Natural Inhibitors Targeting the Gc Glycoprotein of Oropouche Virus: An In Silico Approach.International journal of molecular sciences · 2025Article
- Exploring the challenge of diagnosing and tracking Oropouche virus during Brazil's largest recorded dengue epidemic in 2024.Virology journal · 2025Article
- Oropouche Virus: The Silent Threat of a Re-emerging Arbovirus.Archives of Razi Institute · 2025Review
- Oropouche Virus Importation in Southern Brazil and Emerging Concern Calling for Enhanced Public Health Surveillance.Journal of medical virology · 2025Article
- The Frontier of Entomo-Virology: Applications and Tools for Virus and Vector Surveillance.Pathogens (Basel, Switzerland) · 2025Review
- Challenges in Emerging and Reemerging Arboviral Diseases: The Examples of Oropouche and Yellow Fever.Pathogens (Basel, Switzerland) · 2025Article
- The emergence of oropouche fever: A potential new threat?New microbes and new infections · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oropouche Virus (OROV; genus of Orthobunyavirus) is the causal agent of Oropouche Fever (OF). Due to the lack of specific signs and symptoms and the limited availability of diagnostic tests, the actual epidemiology of OROV infections and OF has been extensively disputed. In this systematic review with meta-analysis, a literature search was carried out in PubMed, Scopus, EMBASE, and MedRxiv in order to retrieve relevant articles on the documented occurrence of OROV infections. Pooled detection rates were then calculated for anti-OROV antibodies and virus detection (i.e., viral RNA detected by viral cultures and/or real-time polymerase chain reaction [RT-qPCR]). Where available, detection rates for other arboviruses (i.e., Dengue [DENV], Chikungunya [CHKV], and Zika Virus [ZIKV]) were calculated and compared to those for OROV. A total of 47 studies from South America and the Caribbean were retrieved. In individuals affected by febrile illness during OROV outbreaks, a documented prevalence of 0.45% (95% confidence interval [95%CI] 0.16 to 1.12) for virus isolation, 12.21% (95%CI 4.96 to 27.09) for seroprevalence (including both IgM and IgG class antibodies), and 12.45% (95%CI 3.28 to 37.39) for the detection of OROV-targeting IgM class antibodies were eventually documented. In the general population, seroprevalence was estimated to be 24.45% (95%CI 7.83 to 55.21) for IgG class antibodies. The OROV detection rate from the cerebrospinal fluids of suspected cases of viral encephalitis was estimated to be 2.40% (95%CI 1.17 to 5.03). The occurrence of OROV infections was consistently lower than that of DENV, CHKV, and ZIKV during outbreaks (Risk Ratio [RR] 24.82, 95%CI 21.12 to 29.16; RR 2.207, 95%CI 1.427 to 3.412; and RR 7.900, 95%CI 5.386 to 11.578, respectively) and in the general population (RR 23.614, 95%CI 20.584 to 27.129; RR 3.103, 95%CI 2.056 to 4.685; and RR 49.500, 95%CI 12.256 to 199.921, respectively). In conclusion, our study stresses the possibly high underestimation of OROV prevalence in the general population of South America, the potential global threat represented by this arbovirus infection, and the potential preventive role of a comprehensive "One Health approach".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.